Abstract 2327
Background
Gliomas are the most common CNS tumors in pediatric patients. Despite extensive efforts, the efficacy of the traditional treatments is limited and the overall prognosis is poor. Data from various studies have indicated a genetic diversity between Pediatric and adult gliomas that may imply for the need of dedicated therapeutic approaches for pediatric gliomas. Using whole-genome sequencing, we have identified a wide variety of genetic alterations in low-grade and high-grade pediatric glioma patients that were found to be of interest in terms of their pattern of occurrence and the availability of targeted inhibitors. These genetic aberrations include novel point mutations, gene fusions and duplications in oncogenic factors such as NTRK2 and FGFR1. In order to study the role of this mutated genes in pediatric glioma and to identify and pre-clinically test new therapeutic targets, in vivo models recapitulating the human disease are required.
Methods
In order to validate the role of the selected mutated genes in pediatric tumorigenesis we cloned these genetic aberrations into Cre-inducible lentiviral vectors and injected them directly into the brain of Cre transgenic post-natal 1 (PN1) pups. In vitro, we used the same lentiviral vectors to transduce embryonic neural stem cells to assess their transformation capacity.
Results
We generated a series of novel pediatric glioma models with different combinations of oncogenes and tumor suppressor genes that leads to high mortality rate. Characterization of these tumors by immunofluorescence staining was consistent with common glioma markers. We also established primary cell lines from the generated tumors that are now being used for functional testing of specific inhibitors. In addition, we performed RNAseq analysis in order to assess the human relevance of these generated mouse models and to elucidate the mechanism of action of these mutations.
Conclusions
We were able to generate novel pediatric glioma mouse models that can be used to examine selected mutations found in human pediatric gliomas and serve as a pre-clinical tool for testing novel therapeutic targets.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
DKFZ-MOST grant.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4925 - Prognostic role of CD73 in metastatic Non Small Cell Lung Cancer according to the presence of driver alterations
Presenter: Giulia Galli
Session: Poster Display session 1
Resources:
Abstract
785 - JAK-STAT inhibitor overcomes interferon γ-reduced, NK cell-mediated cytotoxicity in non-small-cell lung cancer cells
Presenter: Riki Okita
Session: Poster Display session 1
Resources:
Abstract
2326 - Low LATS2 expression is associated with poor prognosis in non small cell lung cancer
Presenter: Si-hyong Jang
Session: Poster Display session 1
Resources:
Abstract
5960 - Application of ESCAT and OncoKB scales in Liquid biopsy (LB) in Advanced NSCLC patients (pts): Is it feasible and reliable?
Presenter: Michael McCusker
Session: Poster Display session 1
Resources:
Abstract
4855 - IDH1R132H mutation induces a less aggressive phenotype of glioma cells and affects the radiosensitivity by interacting with Wnt/β-catenin signaling
Presenter: Xuetao Han
Session: Poster Display session 1
Resources:
Abstract
2641 - Impact of Angiopoietin-2 on glioblastoma response to combined chemo-radiotherapy
Presenter: Charly Helaine
Session: Poster Display session 1
Resources:
Abstract
5743 - The Discovery of RNA-aptamers That Selectively Bind and Inhibit Glioblastoma Stem Cells by targeting EphA2
Presenter: Alessandra Affinito
Session: Poster Display session 1
Resources:
Abstract
4160 - Impact of tumor reoxygenation by nanoparticles on Tumor Associated Macrophages (TAMs)
Presenter: Aurélie Ferré
Session: Poster Display session 1
Resources:
Abstract
2474 - Prognostic significance of c-Rel/p50 heterodimer in the tumor microenvironment of uveal melanoma
Presenter: Seema Kashyap
Session: Poster Display session 1
Resources:
Abstract
1769 - Synergistic role of BAP1 and DNA damage response pathway in uveal melanoma and its prognostic significance.
Presenter: JAYANTI JHA
Session: Poster Display session 1
Resources:
Abstract